Published in N Engl J Med on June 15, 1995
Hormone replacement therapy: assessment of present use, costs, and trends. Br J Gen Pract (1998) 1.67
Estrogen receptor-alpha mediates gender differences in atherosclerosis induced by HIV protease inhibitors. J Biol Chem (2005) 0.81
The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med (1995) 11.08
Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet (1994) 8.34
Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res (1995) 7.42
Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res (1993) 6.31
E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res (1995) 5.11
Estrogen replacement therapy in breast cancer survivors. A time for change. Breast Cancer Committees of the Eastern Cooperative Oncology Group. JAMA (1994) 4.01
Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res (1994) 3.18
Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer Res (2001) 2.50
American Society of Clinical Oncology 1998 update of recommended breast cancer surveillance guidelines. J Clin Oncol (1999) 2.35
Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group. J Clin Oncol (1999) 2.22
Aberrant methylation of the estrogen receptor and E-cadherin 5' CpG islands increases with malignant progression in human breast cancer. Cancer Res (2000) 2.18
Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR. Lancet (2001) 2.16
Sixteen-week dose-intense chemotherapy in the adjuvant treatment of breast cancer. J Natl Cancer Inst (1990) 2.15
Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. Cancer Res (1991) 2.08
Interleukin-3 and bryostatin-1 mediate hyperphosphorylation of BCL2 alpha in association with suppression of apoptosis. J Biol Chem (1994) 1.91
Mapping of ER gene CpG island methylation-specific polymerase chain reaction. Cancer Res (1998) 1.91
Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. Cancer Res (1995) 1.82
Methylation of estrogen and progesterone receptor gene 5' CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors. Clin Cancer Res (1996) 1.77
The loss of estrogen and progesterone receptor gene expression in human breast cancer. J Mammary Gland Biol Neoplasia (1998) 1.75
Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition. Cancer Res (2000) 1.70
Inhibition of fatty acid synthesis induces programmed cell death in human breast cancer cells. Cancer Res (1996) 1.69
DNA methylation in breast cancer. Endocr Relat Cancer (2001) 1.68
Expression of transforming growth factor alpha and its messenger ribonucleic acid in human breast cancer: its regulation by estrogen and its possible functional significance. Mol Endocrinol (1988) 1.59
The estrogen receptor CpG island is methylated in most hematopoietic neoplasms. Cancer Res (1996) 1.56
Phase I trial of interferon gamma to potentiate cyclosporine-induced graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer. J Clin Oncol (1994) 1.50
Role of estrogen receptor gene demethylation and DNA methyltransferase.DNA adduct formation in 5-aza-2'deoxycytidine-induced cytotoxicity in human breast cancer cells. J Biol Chem (1997) 1.32
Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17. Ann Oncol (2008) 1.24
High-dose chemotherapy with reinfusion of purged autologous bone marrow following dose-intense induction as initial therapy for metastatic breast cancer. J Natl Cancer Inst (1991) 1.23
Role of DNA methylation and histone acetylation in steroid receptor expression in breast cancer. J Mammary Gland Biol Neoplasia (2001) 1.23
NCCN Practice Guidelines for Breast Cancer. Oncology (Williston Park) (2000) 1.22
Epidermal growth factor-mediated apoptosis of MDA-MB-468 human breast cancer cells. Cancer Res (1994) 1.19
Modulation of aflatoxin metabolism, aflatoxin-N7-guanine formation, and hepatic tumorigenesis in rats fed ethoxyquin: role of induction of glutathione S-transferases. Cancer Res (1986) 1.11
Oltipraz chemoprevention trial in Qidong, People's Republic of China: study design and clinical outcomes. Cancer Epidemiol Biomarkers Prev (1997) 1.09
Comparison of paclitaxel-, 5-fluoro-2'-deoxyuridine-, and epidermal growth factor (EGF)-induced apoptosis. Evidence for EGF-induced anoikis. J Biol Chem (1999) 1.08
Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer. J Natl Cancer Inst (1995) 1.08
Combined endocrine therapy for breast cancer--new life for an old idea? J Natl Cancer Inst (2000) 1.06
Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole. Ann Oncol (2012) 1.05
High-performance liquid chromatographic separation of natural and synthetic desulphoglucosinolates and their chemical validation by UV, NMR and chemical ionisation-MS methods. Phytochem Anal (2001) 1.03
Induction of programmed cell death in human breast cancer cells by an unsymmetrically alkylated polyamine analogue. Cancer Res (1995) 1.01
Differential effects of bryostatin 1 and phorbol ester on human breast cancer cell lines. Cancer Res (1992) 0.99
Combination of standard cytotoxic agents with polyamine analogues in the treatment of breast cancer cell lines. Clin Cancer Res (2001) 0.98
Oltipraz chemoprevention trial in Qidong, People's Republic of China: modulation of serum aflatoxin albumin adduct biomarkers. Cancer Epidemiol Biomarkers Prev (1998) 0.96
The biology of breast cancer. Hematol Oncol Clin North Am (1999) 0.95
v-rasH induces non-small cell phenotype, with associated growth factors and receptors, in a small cell lung cancer cell line. J Clin Invest (1990) 0.95
The reliability of nipple aspirate and ductal lavage in women at increased risk for breast cancer--a potential tool for breast cancer risk assessment and biomarker evaluation. Cancer Epidemiol Biomarkers Prev (2007) 0.94
Polyamine analogue induction of programmed cell death in human lung tumor cells. Clin Cancer Res (1996) 0.93
Pharmacogenetics in the treatment of breast cancer. Pharmacogenomics J (2004) 0.91
Regulation of estrogen receptor alpha function in breast cancer. Crit Rev Oncog (1997) 0.89
Primary systemic therapy in operable breast cancer. J Clin Oncol (2000) 0.88
Cost-effective manufacture of an allogeneic GM-CSF-secreting breast tumor vaccine in an academic cGMP facility. Cytotherapy (2005) 0.87
Delayed micromolar elevation in intracellular calcium precedes induction of apoptosis in thapsigargin-treated breast cancer cells. Clin Cancer Res (2000) 0.87
Predictive factors for peripheral-blood progenitor-cell collections using a single large-volume leukapheresis after cyclophosphamide and granulocyte-macrophage colony-stimulating factor mobilization. J Clin Oncol (1995) 0.86
Use of two MCF-7 cell variants to evaluate the growth regulatory potential of estrogen-induced products. Cancer Res (1986) 0.86
Expression of DNA methyl-transferase (DMT) and the cell cycle in human breast cancer cells. Oncogene (1999) 0.85
Chemoprotection by inducers of electrophile detoxication enzymes. Basic Life Sci (1993) 0.84
Effects of the polyamine analogues N1-ethyl-N11-((cyclopropyl)methyl)-4,8-diazaundecane and N1-ethylN-11-((cycloheptyl)methyl)-4,8-diazaundecane in human prostate cancer cells. Clin Cancer Res (2000) 0.83
Phase I and pharmacologic study of the alkylating agent modulator novobiocin in combination with high-dose chemotherapy for the treatment of metastatic breast cancer. J Clin Oncol (1995) 0.83
Out of the courtroom and into the clinic. J Clin Oncol (1992) 0.82
Associations between adjuvant endocrine therapy and onset of physical and emotional concerns among breast cancer survivors. Support Care Cancer (2013) 0.82
Programmed cell death in human breast cancer cells. Recent Prog Horm Res (1996) 0.82
Similar breast cancer cell contamination of single-day peripheral-blood progenitor-cell collections obtained after priming with hematopoietic growth factor alone or after cyclophosphamide followed by growth factor. J Clin Oncol (1996) 0.82
Oltipraz chemoprevention trial in Qidong, Jiangsu Province, People's Republic of China. J Cell Biochem Suppl (1997) 0.82
Ovarian ablation as adjuvant therapy for breast cancer. Semin Oncol (2001) 0.81
Use of SERMs for the adjuvant therapy of early-stage breast cancer. Ann N Y Acad Sci (2001) 0.80
Transcriptional control of thymidine kinase gene expression by estrogen and antiestrogens in MCF-7 human breast cancer cells. J Biol Chem (1986) 0.80
Programmed cell death in an estrogen-independent human breast cancer cell line, MDA-MB-468. Cancer Res (1992) 0.79
Paclitaxel induces programmed cell death in MDA-MB-468 human breast cancer cells. Clin Cancer Res (1996) 0.79
Phase I trial of intravenous cyclosporine to induce graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer. J Clin Oncol (1993) 0.79
Bone marrow micrometastases in chemotherapy-responsive advanced breast cancer: effect of ex vivo purging with 4-hydroperoxycyclophosphamide. Cancer Res (1994) 0.78
Sixteen week dose intense chemotherapy for inoperable, locally advanced breast cancer. Breast Cancer Res Treat (1993) 0.78
Pesticides and breast cancer: fact or fad? J Natl Cancer Inst (1997) 0.78
Dose intensity for breast cancer. Oncology (Williston Park) (2001) 0.78
Novobiocin in combination with high-dose chemotherapy for the treatment of advanced breast cancer: a phase 2 study. Biol Blood Marrow Transplant (2000) 0.78
Biomarkers and surrogacy: relevance to chemoprevention. IARC Sci Publ (2001) 0.77
The regulation of estrogen receptor expression and function in human breast cancer. Cancer Treat Res (1998) 0.77
Analysis of factors predicting speed of hematologic recovery after transplantation with 4-hydroperoxycyclophosphamide-purged autologous bone marrow grafts. Bone Marrow Transplant (1991) 0.77
Hepsulfam sensitivity in human breast cancer cell lines: the role of glutathione and glutathione S-transferase in resistance. Cancer Res (1992) 0.77
Effect of hepatocarcinogens on the binding of glucocorticoid-receptor complex in rat liver nuclei. Cancer Res (1976) 0.77
Tamoxifen--panacea or Pandora's box? N Engl J Med (1992) 0.77
Demethylation of the progesterone receptor CpG island is not required for progesterone receptor gene expression. Oncogene (1998) 0.76
Autologous graft-versus-host disease induction in advanced breast cancer: role of peripheral blood progenitor cells. Br J Cancer (2000) 0.76
Comparative analysis of breast cancer contamination in mobilized and nonmobilized hematopoietic grafts. J Hematother (1996) 0.76
Aflatoxin inhibition of glucocorticoid finding capacity of rat liver nuclei. Biochim Biophys Acta (1976) 0.75
A phase I/II study of vinorelbine, doxorubicin, and methotrexate with leucovorin rescue as first-line treatment for metastatic breast cancer. Cancer Chemother Pharmacol (1999) 0.75
Long term follow-up of women treated with 16-week, dose-intensive adjuvant chemotherapy for high risk breast carcinoma. Cancer (1999) 0.75
Adjuvant chemotherapy of axillary lymph-node-positive breast cancer. Cancer Treat Res (1992) 0.75
Apoptosis in hormone-responsive malignancies. Adv Pharmacol (1997) 0.75
CT evaluation of breast cancer: spectrum of disease. Crit Rev Diagn Imaging (1993) 0.75
Breast cancer biology blossoms in the clinic. Nat Med (1998) 0.75
Dose intensity for breast cancer: where do we go from here? Breast Dis (2001) 0.75
Early operable breast cancer. Curr Treat Options Oncol (2000) 0.75
New data on adjuvant therapy for breast cancer. Curr Oncol Rep (1999) 0.75
Breast cancer metastatic to the choroid. J Clin Oncol (1998) 0.75
Combined therapy in advanced breast cancer. Eur J Cancer Clin Oncol (1985) 0.75